donor enriched activated natural killer cell infusion
/ University of Nebraska
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
August 22, 2023
Donor Enriched Activated NK Cell Infusion Post Haploidentical Stem Cell Transplant for Refractory Myeloid Malignancies
(clinicaltrials.gov)
- P1 | N=0 | Withdrawn | Sponsor: University of Nebraska | Trial completion date: Feb 2025 ➔ Apr 2023 | Trial primary completion date: Feb 2025 ➔ Apr 2023
Trial completion date • Trial primary completion date • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology • Transplantation
December 22, 2022
Donor Enriched Activated NK (DEA-NK) Cell Infusion Post Haploidentical Stem Cell Transplant for Refractory Myeloid Malignancies
(clinicaltrials.gov)
- P1 | N=0 | Withdrawn | Sponsor: University of Nebraska | N=18 ➔ 0 | Not yet recruiting ➔ Withdrawn
Enrollment change • Trial withdrawal • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology • Transplantation
May 16, 2022
A Phase I Trial of Donor Enriched Activated NK (DEA-NK) Cell Infusion Post Haploidentical Stem Cell Transplant for Refractory Myeloid Malignancies
(clinicaltrials.gov)
- P1 | N=18 | Not yet recruiting | Sponsor: University of Nebraska
New P1 trial • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology • Transplantation
1 to 3
Of
3
Go to page
1